Arcus Biosciences Inc (RCUS) — Cash Flow-to-Debt Ratio
Arcus Biosciences Inc (RCUS) has a Cash Flow-to-Debt Ratio of -0.29x as of March 2026, meaning its operating cash flow of $-138.00 Million could theoretically repay 0% of its total liabilities ($473.00 Million) in one year. Explore long-term investment intensity of Arcus Biosciences Inc to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Arcus Biosciences Inc Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Arcus Biosciences Inc across 10 annual periods. Also explore RCUS asset base for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Arcus Biosciences Inc (2016–2025)
Year-by-year debt coverage analysis for Arcus Biosciences Inc. For market capitalisation and broader financial context, see Arcus Biosciences Inc market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.95x | $-482.00 Million | $508.00 Million | ▼ -271.2% |
| 2024 | -0.26x | $-170.00 Million | $665.00 Million | ▲ +47.1% |
| 2023 | -0.48x | $-306.00 Million | $633.00 Million | ▼ -175.9% |
| 2022 | 0.64x | $438.00 Million | $688.00 Million | ▲ +286.5% |
| 2021 | -0.34x | $-256.17 Million | $750.45 Million | ▼ -182.9% |
| 2020 | 0.41x | $111.17 Million | $269.99 Million | ▲ +122.0% |
| 2019 | -1.87x | $-73.46 Million | $39.27 Million | ▼ -74.0% |
| 2018 | -1.08x | $-43.00 Million | $39.98 Million | ▼ -57.1% |
| 2017 | -0.68x | $-25.06 Million | $36.62 Million | ▲ +45.9% |
| 2016 | -1.26x | $-12.94 Million | $10.24 Million | — |